Galapagos raises $300M on the back of first PhIII filgotinib success; Incyte pushes into PhIII with topical Jakafi
→ Galapagos $GLPG wasn’t about to let the success of its first Phase III for filgotinib — handled by lead partner Gilead — go by without a quick raise. The biotech garnered $300 million from the sale of its stock.
→ Incyte $INCY says its Phase IIb study for a cream formulation of Jakafi (ruxolitinib) produced promising results for patients with atopic dermatitis. Researchers are now moving ahead with a Phase III registration program.
→ Principia BioPharma is now boosting the size of its proposed IPO. The South San Francisci-based biotech wants to sell 6.3 million shares at a price range of $15 to $17.